Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. - Wikidata - awgldk - TriplyDB

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q46592694

about

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.Prior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in china The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.Role of allo-SCT for CML in 2010.Stem cell transplant for chronic myeloid leukemia in the imatinib era Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Allogeneic transplantation for CML in the TKI era: striking the right balance.Allogeneic transplant for chronic myeloid leukemia in 2010.Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.

P2860

Q34198055-8A535175-E92E-427E-B024-97C7D66930BD Q35480678-7491D4C2-21AC-4B2C-942F-CDA537CA7D40 Q35628978-927EF1B4-8AAF-4FA1-931B-B5402F465C3D Q35633858-570CA6A3-B467-453C-9F65-3941B71311E2 Q36059184-D20B2F43-4325-4C10-8CC6-D93A37E97DAF Q36822880-5564262E-A0FF-4EB8-B3EA-D3432BE202B0 Q37428676-0047F95D-6E18-47E8-90D1-0627F5450BEA Q37497977-9DF0FA72-4826-46E4-A8DD-84AF60FB48FB Q37657492-23A44C05-04DD-4669-98CD-F7316C774126 Q37763493-AA65E1BF-8DA2-43A3-B5D5-A82760D2F37D Q37793491-D241945D-BF68-49A7-ACB1-9BDAC16E1A5F Q37853793-4DF4E400-CEF3-47DB-BF1C-154E6CD2F57F Q38634736-42F9408D-3D71-4D7C-BB74-8ED96A2EB500 Q41874881-151F6811-EDED-4B12-B4A0-7E211FC7D445 Q46127678-09FC02D0-1F19-4667-B726-4EED065D838B

P2860

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

http://www.wikidata.org/entity/Q46592694

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@en

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@nl

type

label

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@en

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@nl

prefLabel

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@en

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@nl

P1433

Q46592694-A9C6C4DD-7E04-4AAE-A9A7-DAA3966EEF07

P1476

Q46592694-6BB2EE65-EBC3-466A-B7AB-CD84D7CE1526

P2093

Q46592694-011B6B20-3368-49C3-9F21-850DC195A35C

Q46592694-060A76EB-E57D-4403-AEAC-3B26FE9C3E44

Q46592694-1C83F75E-5E33-4811-A6F6-07DE49D3A3E9

Q46592694-3ABD94D3-AF8A-4ED8-A0B7-FAF6CF74AA53

Q46592694-5723A673-99CD-4B05-8212-86D348F238D5

Q46592694-5A4A137D-BD93-4018-812C-70D189CAD6A7

Q46592694-5AAC2437-286C-4F9E-B971-54A0EFD09E42

Q46592694-B5C23E23-3551-479D-A7F7-17C52FEA1EDE

Q46592694-D0FAA61A-E9F2-45D4-B9F2-F1F4BA8E11C6

Q46592694-F2B774F0-45B9-42B9-B5F6-493DFE3263EB

P2860

Q46592694-017DC667-1C8E-436D-ACE1-970CE33DA21A

Q46592694-026E83A5-0C32-453D-B5AC-087EB3613558

Q46592694-0FDEB3D2-431E-422B-B4A6-1E69A63EDAB4

Q46592694-2636E784-094B-4D59-BBC3-466C6FA224F0

Q46592694-3B5B4F07-6DA3-4DB3-856E-94B86ABCB802

Q46592694-44E3A4DF-8868-4649-B02E-9CB66DFEFA0E

Q46592694-487CD358-A78A-4CED-A4E6-DF80BD37501C

Q46592694-5FFCDB70-5519-4038-B2F8-E88A4007046C

Q46592694-65CC3C83-A36C-4D73-839C-012E1140120E

Q46592694-6808A6A2-F391-4757-813D-9CBD0CB2931C

P2888

Q46592694-BDC795B3-5BD9-4A0F-B50E-ED1CBE68F1F5

P304

Q46592694-C3A023AC-49FF-4CD8-82BA-6082FBEA930A

P31

Q46592694-6EF371F8-8F0D-46CE-9F51-2AE406A4985F

P356

Q46592694-29F90EE2-E382-4CC7-9078-0B990C2F9603

P407

Q46592694-BFE769A5-1BEF-4F27-A4AD-762543CBB63D

P433

Q46592694-A8CBD7C5-C6DC-490E-979F-48EC6F3AB927

P478

Q46592694-50D486F1-DFD0-407A-9112-94B43DD2DA92

P577

Q46592694-51DFCA65-9EDF-484E-BDDE-C38F33F6E2D8

P6179

Q46592694-8E1747FD-2B57-4CC6-BB73-41AB7FCEED61

P698

Q46592694-D5DD86C0-59D4-4868-93B5-93E73FE9F544

P356

P1433

Bone Marrow Transplantation

P1476

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

@en

P2093

Balon J

http://www.w3.org/2001/XMLSchema#string

Giebel S

http://www.w3.org/2001/XMLSchema#string

Gooley TA

http://www.w3.org/2001/XMLSchema#string

Hellmann A

http://www.w3.org/2001/XMLSchema#string

Hołowiecki J

http://www.w3.org/2001/XMLSchema#string

Kałwak K

http://www.w3.org/2001/XMLSchema#string

Kruzel T

http://www.w3.org/2001/XMLSchema#string

Prejzner W

http://www.w3.org/2001/XMLSchema#string

Szatkowski D

http://www.w3.org/2001/XMLSchema#string

Wojnar J

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Imatinib mesylate--a new oral targeted therapy.

Practical management of patients with chronic myeloid leukemia receiving imatinib.

Imatinib treatment: specific issues related to safety, fertility, and pregnancy.

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.

P2888

P304

417-424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705087

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037387036

http://www.w3.org/2001/XMLSchema#string

P698

16007105

http://www.w3.org/2001/XMLSchema#string